These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10597734)

  • 21. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
    Maeda H; Hori S; Nishitoh H; Ichijo H; Ogawa O; Kakehi Y; Kakizuka A
    Cancer Res; 2001 Jul; 61(14):5432-40. PubMed ID: 11454688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug development in prostate cancer.
    Ripple GH; Wilding G
    Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targets of selenium in prostate cancer prevention (Review).
    Abdulah R; Kobayashi K; Yamazaki C; Koyama H
    Int J Oncol; 2011 Aug; 39(2):301-9. PubMed ID: 21567081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel targets in gastric and esophageal cancer.
    Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of anti-angiogenesis therapy for prostate cancer.
    Jiménez JA; Kao C; Raikwar S; Gardner TA
    Urol Oncol; 2006; 24(3):260-8. PubMed ID: 16678061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
    Strother JM; Beer TM; Dreicer R
    Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
    London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
    Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
    Lee MV; Fong EM; Singer FR; Guenette RS
    Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
    Gupta S; Ahmad N; Nieminen AL; Mukhtar H
    Toxicol Appl Pharmacol; 2000 Apr; 164(1):82-90. PubMed ID: 10739747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
    O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
    Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer.
    Howard EW; Ling MT; Chua CW; Cheung HW; Wang X; Wong YC
    Clin Cancer Res; 2007 Mar; 13(6):1847-56. PubMed ID: 17363541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New molecular targets and novel agents in the treatment of advanced urothelial cancer.
    Beekman KW; Bradley D; Hussain M
    Semin Oncol; 2007 Apr; 34(2):154-64. PubMed ID: 17382799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting advanced prostate cancer.
    Fillon M
    J Natl Cancer Inst; 2011 Dec; 103(23):1733. PubMed ID: 22100582
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiangiogenesis: a possible treatment option for prostate cancer?
    Longoria RL; Cox MC; Figg WD
    Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Novel targets for cancer chemotherapy].
    Inoue S
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):191-201. PubMed ID: 8611047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy in prostate cancer.
    Corcoran NM; Gleave ME
    Histopathology; 2012 Jan; 60(1):216-31. PubMed ID: 22212088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future developments of nonhormonal systemic therapy for prostatic carcinoma.
    Warner JA; Heston WD
    Urol Clin North Am; 1991 Feb; 18(1):25-33. PubMed ID: 1992572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).
    Papatsoris AG; Karamouzis MV; Papavassiliou AG
    Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.